
Novelix Pharmaceuticals Ltd is Rated Hold by MarketsMOJO
2026-11-18 10:10:05Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 November 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Novelix Pharmaceuticals Ltd Reports Very Positive Quarterly Financial Performance Amid Margin Expansion
2026-11-16 08:00:08Novelix Pharmaceuticals Ltd has delivered a very positive financial performance for the quarter ended September 2026, marking a significant improvement in revenue growth and profitability metrics compared to its historical trends. Despite operating within the retailing sector as a micro-cap entity, the company’s recent results demonstrate robust operational efficiency and margin expansion, signalling a favourable shift in its financial trajectory.
Read MoreNovelix Pharmaceuticals Gains 8.34%: Key Drivers Behind This Week’s Rally
2026-11-15 14:00:05Key Events This Week Nov 09: Stock opens at Rs.63.24, down 2.20% amid broader market gains Nov 11: Sharp rebound with 5.98% gain to Rs.67.02 following positive quarterly results Nov 12: Continued rally to Rs.69.12 as valuation shifts to fair from attractive Nov 13: Week closes at Rs.70.05, up 1.35% despite Sensex decline Week OpenRs.64.66 <div cla...
Read More
Novelix Pharmaceuticals Ltd Reports Positive Quarterly Growth Amid Financial Trend Adjustment
2026-11-12 11:00:10Novelix Pharmaceuticals Ltd has demonstrated a positive financial performance in the quarter ended September 2026, marking a shift from a previously very positive trend to a positive one. The company’s net sales surged by 21.8% compared to the previous four-quarter average, while profitability metrics reached record highs, signalling robust operational execution despite a slight moderation in its overall financial trend score.
Read More
Novelix Pharmaceuticals Ltd: Valuation Shifts Signal Renewed Price Attractiveness
2026-11-04 08:00:19Novelix Pharmaceuticals Ltd, a micro-cap player in the retailing sector, has seen its valuation parameters shift favourably, moving from fair to attractive territory despite a recent dip in share price. This change comes amid a backdrop of mixed returns relative to the broader Sensex index, prompting investors to reassess the stock’s price attractiveness and growth prospects.
Read More
Novelix Pharmaceuticals Ltd is Rated Hold by MarketsMOJO
2026-10-28 10:10:04Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read More
Novelix Pharmaceuticals Ltd is Rated Hold by MarketsMOJO
2026-10-17 10:10:44Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Novelix Pharmaceuticals Ltd is Rated Hold
2026-10-06 10:11:00Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read More
Novelix Pharmaceuticals Ltd is Rated Hold
2026-09-25 10:11:00Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 Sep 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read MoreAnnouncement Under Regulation 30 (LODR)- Opening Of Corporate Office.
17-Nov-2026 | Source : BSEAnnouncement under Regulation 30 (LODR)-Newspaper Publication
14-Nov-2026 | Source : BSENewspaper publication of Results for September 2026 quarter.
Announcement Under Regulation 30 (LODR)- Supply Agreement
13-Nov-2026 | Source : BSESubmission of Supply agreement intimation.
Corporate Actions
No Upcoming Board Meetings
Novelix Pharmaceuticals Ltd has declared 3% dividend, ex-date: 16 Aug 12
Novelix Pharmaceuticals Ltd has announced 10:1 stock split, ex-date: 04 Oct 10
No Bonus history available
No Rights history available